Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2021

Open Access 01-12-2021 | Antibiotic | Review

Novel therapeutic interventions towards improved management of septic arthritis

Authors: Jian Wang, Liucai Wang

Published in: BMC Musculoskeletal Disorders | Issue 1/2021

Login to get access

Abstract

Septic arthritis (SA) represents a medical emergency that needs immediate diagnosis and urgent treatment. Despite aggressive treatment and rapid diagnosis of the causative agent, the mortality and lifelong disability, associated with septic arthritis remain high as close to 11%. Moreover, with the rise in drug resistance, the rates of failure of conventional antibiotic therapy have also increased. Among the etiological agents frequently isolated from cases of septic arthritis, Staphylococcus aureus emerges as a dominating pathogen, and to worsen, the rise in methicillin-resistant S. aureus (MRSA) isolates in bone and joint infections is worrisome. MRSA associated cases of septic arthritis exhibit higher mortality, longer hospital stay, and higher treatment failure with poorer clinical outcomes as compared to cases caused by the sensitive strain i.e methicillin-sensitive S. aureus (MSSA).
In addition to this, equal or even greater damage is imposed by the exacerbated immune response mounted by the patient’s body in a futile attempt to eradicate the bacteria. The antibiotic therapy may not be sufficient enough to control the progression of damage to the joint involved thus, adding to higher mortality and disability rates despite the prompt and timely start of treatment. This situation implies that efforts and focus towards studying/understanding new strategies for improved management of sepsis arthritis is prudent and worth exploring.
The review article aims to give a complete insight into the new therapeutic approaches studied by workers lately in this field. To the best of our knowledge studies highlighting the novel therapeutic strategies against septic arthritis are limited in the literature, although articles on pathogenic mechanism and choice of antibiotics for therapy, current treatment algorithms followed have been discussed by workers in the past. The present study presents and discusses the new alternative approaches, their mechanism of action, proof of concept, and work done so far towards their clinical success. This will surely help to enlighten the researchers with comprehensive knowledge of the new interventions that can be used as an adjunct therapy along with conventional treatment protocol for improved success rates.
Literature
1.
2.
Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults. Lancet. 2010;375:846–55.PubMedCrossRef
3.
Lynn MM, Mathews CJ. Advances in the management of bacterial septic arthritis. Int J Clin Rheumatol. 2012;7(3):335–42.CrossRef
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Minguez S, Molinos S, Mateo L. Septic arthritis due to methicillin-resistant Staphylococcus aureus in adults. Reumatol Clin. 2015;11(November-December (6)):381–386
20.
21.
22.
Lidgren L. Septic arthritis and osteomyelitis. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology. Toronto: Mosby; 2003:1055-1066.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Al-Nammari SS, Bobak P, Venkatesh R. Methicillin resistant Staphylococcus aureus versus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis. Arch Orthop Trauma Surg. 2007;127(7):537–42.PubMedCrossRef
32.
Combs K, Cox K. Clinical outcomes involving patients that develop septic arthritis with methicillin sensitive Staphylococcus aureus versus methicillin resistant Staphylococcus aureus. J Orthop. 2017;15(1):9–12.PubMedPubMedCentralCrossRef
33.
34.
35.
36.
37.
38.
Krieg AM. A possible cause of joint destruction in septic arthritis. Arthritis Res Ther. 1999;1:3.CrossRef
39.
40.
41.
42.
43.
44.
45.
Haywood L, Walsh DA. Vasculature of the normal and arthritic synovial joint. Histol Histopathol. 2001;16:277–84.PubMed
46.
47.
Hasan S, Smith JW. Septic arthritis. Curr Treat Options Infect Dis. 2001;3:279–86.
48.
49.
50.
Arciola CR, Campoccia D, Ehrlich GD, Montanaro L. Biofilm-based implant infections in orthopaedics. Adv Exp Med Biol. 2015;830:29–46.PubMedCrossRef
51.
52.
Biswas R, Voggu L, Simon UK, Hentschel P, Thumm G, Gotz F. Activity of the major staphylococcal autolysin Atl. FEMS Microbiol Lett. 2006;259:260–8.PubMedCrossRef
53.
54.
55.
Ryding U, Flock JI, Flock M, Soderquist B, Christensson B. Expression of collagen-binding protein and types 5 and 8 capsular polysaccharide in clinical isolates of Staphylococcus aureus. J Infect Dis. 1997;176:1096–9.PubMedCrossRef
56.
Nilsson IM, Hartford O, Foster T, Tarkowski A. Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect. Immun. 1999;67:1045–9.PubMedPubMedCentralCrossRef
57.
58.
59.
60.
61.
Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis. 2006;43(8):961–7.PubMedCrossRef
62.
McConoughey SJ, Howlin R, Granger JF, et al. Biofilms in periprosthetic orthopedic infections [published correction appears in Future Microbiol. 2014; 9(10):1234]. Future Microbiol. 2014;9(8):987–1007.PubMedCrossRef
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
Dodwell ER. Osteomyelitis and septic arthritis in children: current concepts. Curr Opin Pediatr. 2013;25(1):58–63.PubMedCrossRef
73.
74.
Papathanasiou I, Malizos KN, Poultsides L. The catabolic role of toll-like receptor 2 (TLR-2) mediated by the NF-kB pathway in septic arthritis. J Orthop Res. 2011;29(2):247–51.PubMedCrossRef
75.
76.
Bremell T, Tarkowski A. Preferential induction of septic arthritis and mortality by superantigen-producing staphylococci. Infect. Immun. 1995;63:4185–7.PubMedPubMedCentralCrossRef
77.
Tarkowski A, Bokarewa M, Collins LV, Gjertsson I, Hultgren OH, Jin T, et al. Current status of pathogenetic mechanisms in staphylococcal arthritis. FEMS Microbiol Letters. 2002;217:125–32.CrossRef
78.
79.
80.
Mitchell M, Howard B, Haller J, Sartoris DJ, Resnick D. Septic arthritis. Radiol. Clin. North Am. 1988;26:1295–313.PubMedCrossRef
81.
82.
83.
84.
85.
86.
87.
Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11(7):3919–31.PubMedPubMedCentral
88.
89.
90.
91.
92.
Mahlapuu M, Hakansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.PubMedPubMedCentralCrossRef
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
Reffuveille F, de la Fuente-Núñez C, Mansour S, Hancock RE. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother. 2014;58(9):5363–71.PubMedPubMedCentralCrossRef
107.
108.
109.
Paulsen F, Pufe T, Conradi L, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol. 2002;198:369–77.PubMedCrossRef
110.
Paulsen F, Pufe T, Petersen W, Tillmann B. Expression of natural peptide antibiotics in human articular cartilage and synovial membrane. Clin Diagn Lab Immunol. 2001;8:1021–3.PubMedPubMedCentralCrossRef
111.
112.
113.
Yazici H, O'Neill MB, Kacar T, et al. Engineered Chimeric Peptides as Antimicrobial Surface Coating Agents toward Infection-Free Implants. ACS Appl Mater Interfaces. 2016;8(8):5070–81.PubMedPubMedCentralCrossRef
114.
de Breij A, Riool M, Kwakman PH, et al. Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145. J Control Release. 2016;222:1–8.PubMedCrossRef
115.
116.
117.
Kang J, Dietz MJ, Li B. 2019.Antimicrobial peptide LL-37 is bactericidal against Staphylococcus aureus biofilms. PLoS One. 14(6):e0216676.
118.
Chen J, Shi X, Zhu Y, et al. On-demand storage and release of antimicrobial peptides using Pandora's box-like nanotubes gated with a bacterial infection-responsive polymer. Theranostics. 2020;10(1):109–22.PubMedPubMedCentralCrossRef
119.
120.
Duckworth D, Gulig P. Bacteriophage: potential treatment for bacterial infections. Biodrugs. 2002;16:57–62.PubMedCrossRef
121.
Azeredo J, Sutherland IW. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol. 2008;9:261–6.PubMedCrossRef
122.
123.
Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–5.PubMedCrossRef
124.
Bedi MS, Verma V, Chhibber S. Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotechnol. 2009;25:1145–51.CrossRef
125.
126.
Kaur S, Harjai K, Chhibber S. In vivo assessment of phage and linezolid based implant coatings for treatment of methicillin resistant S. aureus (MRSA) mediated orthopaedic device related infections. PLoS One. 2016;11(6):e0157626.PubMedPubMedCentralCrossRef
127.
128.
129.
Taati MM, Khoshbayan A, Chegini Z, Farahani I, Shariati A. Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials. Drug Des Devel Ther. 2020;14:1867–83.CrossRef
130.
131.
132.
133.
134.
Maciejewska B, Olszak T, Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl Microbiol Biotechnol. 2018;102(6):2563–81.PubMedPubMedCentralCrossRef
135.
136.
Jevon M, Guo C, Ma B, Mordan N, Nair SP, Harris M, et al. Mechanisms of internalization of Staphylococcus aureus by cultured human osteoblasts. Infect Immun. 1999;67:2677–81.PubMedPubMedCentralCrossRef
137.
Ellington JK, Reilly SS, Ramp WK, Smeltzer MS, Kellam JF, Hudson MC. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb Pathog. 1999;26:317–23.PubMedCrossRef
138.
Garzoni C, Kelley WL. Staphylococcus aureus : new evidence for intracellular persistence. Trends Microbiol. 2009;17:59–65.PubMedCrossRef
139.
140.
141.
Zhang L, Sun L, Wei R, et al. Intracellular Staphylococcus aureus Control by Virulent Bacteriophages within MAC-T Bovine Mammary Epithelial Cells. Antimicrob Agents Chemother. 2017;61(2):e01990–16.PubMedPubMedCentralCrossRef
142.
143.
144.
145.
146.
147.
Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M. Pro-and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep. 2017;7(1):1–13.
148.
149.
150.
151.
152.
Kishor C, Mishra RR, Saraf SK, Kumar M, Srivastav AK, Nath G. Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res. 2016;143(1):87–94.PubMedPubMedCentralCrossRef
153.
154.
155.
156.
157.
158.
159.
160.
161.
Ferry T, Batailler C, Petitjean C, Chateau J, Fevre C, Forestier E, et al. The potential innovative use of bacteriophages within the DAC® hydrogel to treat patients with knee megaprosthesis infection requiring "debridement antibiotics and implant retention" and soft tissue coverage as salvage therapy. Front Med (Lausanne). 2020;7:342. https://​doi.​org/​10.​3389/​fmed.​2020.​00342.CrossRef
162.
Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly (ester amide) s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002;41(7):453–8. https://​doi.​org/​10.​1046/​j.​1365-4362.​2002.​01451.​x PMID: 12121566.CrossRefPubMed
163.
Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, et al. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005;30:23–6. https://​doi.​org/​10.​1111/​j.​1365-2230.​2004.​01600.CrossRefPubMed
164.
165.
166.
167.
168.
Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000;59:455.PubMedPubMedCentralCrossRef
169.
170.
171.
172.
Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa) B mediated induction of MT1-MMP. J Cell Sci. 2001;114(Pt 1):131–9.PubMedCrossRef
173.
174.
175.
176.
Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol. 1998;161:3340.PubMedCrossRef
177.
178.
179.
Gjertsson I, Hultgren OH, Tarkowski A. Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance. Clin Exp Immunol. 2002;130(3):409–14.PubMedPubMedCentralCrossRef
180.
Puliti M, von Hunolstein C, Bistoni F, et al. The beneficial effect of interleukin-12 on arthritis induced by group B streptococci is mediated by interferon-γ and interleukin-10 production. Arthritis Rheum. 2002;46(3):806–17.PubMedCrossRef
181.
Hultgren O, Kopf M, Tarkowski A. Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth. J Immunol. 1998;160(10):5082–7. 9590259.PubMedCrossRef
182.
183.
184.
185.
186.
187.
188.
Metadata
Title
Novel therapeutic interventions towards improved management of septic arthritis
Authors
Jian Wang
Liucai Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2021
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-021-04383-6

Other articles of this Issue 1/2021

BMC Musculoskeletal Disorders 1/2021 Go to the issue

Study protocol

Cryoneurolysis for the management of chronic pain in patients with knee osteoarthritis; a double-blinded randomized controlled sham trial

Research

A predictive model for hip abductor strength and knee extensor strength 12 months after total hip arthroplasty with an interaction term

Research

Comparing ERAS-outpatient versus standard-inpatient hip and knee replacements: a mixed methods study exploring the experience of patients who underwent both

Case report

Malignant phosphaturic mesenchymal tumor-ossifying fibroma-like subtype: a case report and literature review

Research

Implications of gender-based variabilities in bone mineral density and hemoglobin levels

Research article

Biomechanical characteristics of tibio-femoral joint after partial medial meniscectomy in different flexion angles: a finite element analysis